- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02396056
Enhancing Guided Bone Regeneration by Modifying a Resorbable Membrane
Enhanced Guided Bone Regeneration in Localized Osseous Alveolar Defects by Using a Novel Perforated Resorbable Barrier Membrane
Guided bone regeneration (GBR) procedures have significantly evolved over the last 20 years. Significant advances have been made with various barrier membranes with or without the use of bone grafts and other materials. Some of the main limitations of non-resorbable barriers included cytotoxicity and need for removal, which can adversely affect the regenerated bone volume. Similar GBR success has been documented extensively with cell occlusive resorbable barriers membranes. Recently, the investigators demonstrated supracrestal bone regeneration in guided tissue regeneration procedures in humans with the use of novel perforated barrier membrane (MPM). The perforation allows mesenchymal stem cells and other progenitor cells present in the gingival tissues to migrate into the osseous defect and contribute to the osseous regeneration potential.
The objective of this study is to investigate the GBR potential of MPM in alveolar ridge defects, relative to a similar occlusive barrier. Ten non-smoking patients that need localized alveolar ridge augmentation prior to implant placement will be included into the study. Patients will be divided into two groups, as follows: occlusive bovine collagen membrane (OM control group, 5 patients) and modified bovine perforated collagen membrane (MPM test group, 5 patients). All sites will be grafted with mineralized cortical bone allograft and when needed cortical bone pins will be use for site stability. A Cone Bean (CT) will be obtained prior to surgery and 6-8 months post treatment from which volumetric width changes will be quantify. A bone biopsy will be obtained at the time of implant placement (~6-8 months) to determine residual graft particles and new bone formation. Dimensional width changes will be assess at 6-8 months during re-entry for implant placement. Soft tissue healing will be assessed at 2, 4, 8, 16 weeks and 6 months.
This study can potentially impact current bone augmentation techniques and may lead to the modification of existing commercial membranes that will enhance site development prior to implant placement. The contribution of progenitor cells to the osseous defect might lead to greater bone formation and possible faster wound healing.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Julio A Carrion, DMD, PhD
- Phone Number: 631-632-9443
- Email: julio.carrion@stonybrook.edu
Study Contact Backup
- Name: Vincent J Iacono, DMD
- Phone Number: 631-632-8955
- Email: vincent.iacono@stonybrook.edu
Study Locations
-
-
New York
-
Stony Brook, New York, United States, 11794
- Recruiting
- School of Dental Medicine of Stony Brook University
-
Contact:
- Julio A Carrion, DMD, PhD
- Phone Number: 631-632-9443
- Email: julio.carrion@stonybrook.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- at the augmentation site, the alveolar ridge must be deficient in a buccolingual dimension (< 5.5 mm): Class 1 Seibert defects.
- alveolar ridges to be augmented must have a minimum of 4 mm of keratinized gingiva extending the length of the planned augmentation.
Exclusion Criteria:
- general contraindications to implant surgery
- subjected to irradiation, chemotherapy or immunosuppressive therapy over the past 5 years
- poor oral hygiene and motivation
- uncontrolled diabetes
- pregnant or lactating
- substance abusers
- current smokers
- psychiatric problems or unrealistic expectations
- acute infection in the area intended for implant placement
- positive to HIV and hepatitis B and C
- affected by autoimmune diseases such as arthritis rheumatoid, systemic lupus erythematosus, sclerodermia, Sjo ̈gren syndrome and dermatomyositis polymyositis
- treated or under treatment with intravenous amino-bisphosphonates
- subjected previously to reconstructive procedures of the posterior mandible and
- under chronic treatment with steroids or non-steroidal anti-inflammatory drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Occlusive Membrane (OM)
Five patients will be randomly assigned to the OM group.
|
Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
|
Experimental: Modified Perforated Membrane (MPM)
Five patients will be randomly assigned to the MPM group.
|
Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical horizontal bone augmentation results through direct measurement.
Time Frame: at 6 months post treatment
|
at 6 months post treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Volumetric measurements with CBCT
Time Frame: pre- and 6 months post treatment
|
pre- and 6 months post treatment
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
De novo bone formation, and residual graft particles quantification with histomorphometric analysis
Time Frame: at 6 months post treatment
|
at 6 months post treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- StonyBrookU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alveolar Ridge Augmentation
-
Cliniques universitaires Saint-Luc- Université...Geistlich Pharma AGRecruitingAlveolar Ridge AugmentationBelgium
-
Cairo UniversityUnknownAlveolar Ridge AugmentationEgypt
-
Hadassah Medical OrganizationCompleted
-
University of Central LancashireImperial College LondonNot yet recruitingAlveolar Ridge AugmentationUnited Kingdom
-
Mansoura UniversityCompletedAlveolar Ridge AugmentationEgypt
-
University of Santiago de CompostelaFriedrich-Alexander-Universität Erlangen-NürnbergActive, not recruiting
-
University of LouisvilleCompleted
-
Scil Technology GmbHFGK Clinical Research GmbHUnknownAlveolar Ridge AugmentationGermany
-
University of BernCompletedAlveolar Ridge AugmentationSwitzerland
-
Ugur GULSENCompletedAlveolar Ridge Augmentation
Clinical Trials on BioMend Extend
-
University of Sao PauloCompletedAlveolar Process
-
Duke UniversityNational Institute of Nursing Research (NINR)Active, not recruitingHypertension | Diabetes Mellitus, Type 2United States
-
Second Affiliated Hospital, School of Medicine,...RecruitingIntrahepatic CholangiocarcinomaChina, United States
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2United States
-
St. Joseph's Healthcare HamiltonNot yet recruiting
-
Xiaodong SunShanghai Zhongshan Hospital; Eye & ENT Hospital of Fudan University; Shanghai... and other collaboratorsUnknownAge-related Macular DegenerationChina
-
St. Olavs HospitalNorwegian University of Science and Technology; Alesund Hospital; Molde HospitalRecruitingWet Macular DegenerationNorway
-
St. Joseph's Healthcare HamiltonRecruitingLung Cancer | Thoracic Cancer | Lung NeoplasmCanada
-
First Affiliated Hospital of Chongqing Medical...Enrolling by invitationExudative Age-Related Macular DegenerationChina
-
Novartis PharmaceuticalsCompletedDiabetic Macular EdemaTurkey